Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant T-VEC + nivolumab for resectable stage IIIB/C/D-IV M1a melanoma
NL-OMON49074Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec and nivolumab in melanoma and cutaneous malignancy, sponsored by Netherlands Cancer Institute. Primary endpoint: Pathologic response rate. Started Oct 2020; status: completed.
02
Drugs
talimogene laherparepvecnivolumab
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON49074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49074.